An observational study in Cardiac Angiosarcoma, sponsored by Immune Oncology Research Institute. Recruiting at 1 site in Armenia. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Immune Oncology Research Institute · Observational
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:
Primary cardiac angiosarcoma arises directly within the heart, unlike secondary cardiac tumors that originate from elsewhere in the body. While it predominantly affects the right side of the heart, particularly the right atrium, it can also impact other cardiac chambers and structures. The characteristic feature of cardiac angiosarcoma is the rapid formation of abnormal blood vessels that invade the myocardium, leading to the destruction of healthy heart tissue.The five-year survival rate for patients with primary cardiac angiosarcoma (PCA) is reported to be around 14%. In contrast, familial variants of this malignancy exhibit even more severe outcomes, with a mean survival rate of only 4 months.
Establishing an international registry for cardiac angiosarcomas is crucial for several reasons:
Creating an international registry for cardiac angiosarcoma is crucial for better understanding this aggressive cancer. It will help address the rising cancer burden and support research and treatment advancements that could improve patient survival rates and prevention.
The following data will be collected through questionnaires:
Quality control and data management will be done by the Immune Oncology Research Institute.
99 studies on the registry are indexed under Hemangiosarcoma; 16 are open to participants now.
Browse Hemangiosarcoma studies →Immune Oncology Research Institute is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients diagnosed with Cardiac Angiosarcoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6-month overall survival
Time frame: 6 months
1-year overall survival
Time frame: 1 year
6-month progression free survival
Time frame: 6 months
1-year progression free survival
Time frame: 1 year
3-year progression free survival
Time frame: 3 years
6-month event-free survival
Time frame: 6 months
1-year event-free survival
Time frame: 1 year
3-year event-free survival
Time frame: 3 years
Complete remission rate
Time frame: 5 years
Started May 2025 (actual). Primary completion is estimated for May 2035, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immune Oncology Research Institute